Solvonis Therapeutics

Solvonis Therapeutics is a clinical-stage biopharmaceutical company developing treatments for addiction and mental health disorders.

Its lead programme is in Phase III for severe alcohol use disorder, with additional programmes addressing moderate to severe alcohol use disorder, post-traumatic stress disorder and stimulant addiction.

The company also uses an AI-supported discovery platform to investigate treatments for central nervous system conditions alongside its clinical development work.